#USA #Minneapolis #Medical Devices #VentureMed #FLEX Vessel

VentureMed Group's Significant Series C Funding Round

On October 30, 2025, VentureMed Group, Inc., an innovative medical technology company based in Minnesota, announced the successful completion of a $28 million Series C financing round. This funding was primarily led by S3 Ventures, alongside contributions from existing investors including Endeavour Vision. The capital raised will primarily focus on accelerating the commercial launch of its flagship product, the FLEX Vessel Prep™ System, while also expanding its clinical applications for treating vascular access issues.

Denis Harrington, the President and CEO of VentureMed, expressed gratitude towards their current investors, stating, "We are thankful for the continued support of our existing investors and are excited to welcome new partners to our consortium. This significant funding highlights investor confidence in our FLEX Vessel Prep™ System and our mission to enhance our position in the global vascular care market."

The financial injection will strengthen VentureMed's commercial infrastructure and propel the clinical program forward, facilitating the development of new products, particularly within adjacent vascular fields. The need for improved vascular access solutions is critical, as vascular diseases continue to be a growing burden globally, exacerbated by rising rates of obesity, diabetes, and high blood pressure. With over 20 million individuals affected by peripheral artery disease (PAD) in the United States and more than 200 million worldwide, the necessity for innovative treatment methods is more pressing than ever.

Brian R. Smith, Managing Director at S3 Ventures, highlighted the transformative nature of VentureMed's technology, stating, "VentureMed is tackling one of the largest challenges in vascular access with a technology that is both elegant and transformative. Our partnership reflects our shared mission to provide breakthrough therapies to those who need them most."

One of the major challenges within this field is the ongoing cycle of revascularization and repeated interventions, which place a heavy burden on patients and healthcare systems. The FLEX Vessel Prep™ System aims to improve vessel compliance, minimize trauma, and achieve better long-term outcomes for patients.

Dr. Ari Kramer, General Surgeon at Spartanburg Medical Center, emphasized that lesion preparation is rapidly evolving into one of the most crucial procedures for enhancing patient outcomes. He describes the FLEX VP System as a leader in arteriovenous access interventions. "This fundraising marks a significant milestone as the company seeks further clinical evidence and expanded indications, ultimately redefining vessel preparation and broadening treatment options on a global scale."

The FLEX Vessel Prep™ System has obtained FDA 510(k) clearance and carries the CE mark, positioning it effectively within the medical market. Furthermore, it is supported in the U.S. by a unique CMS HCPCS code (C1600) designed for transitional payments, setting the stage for industry-wide adoption of this innovative technology.

In conclusion, Alexander Schmitz, Partner at Endeavour Vision, highlighted the value of reducing the need for repeated interventions, correlating it with improved patient outcomes while aligning with the shift towards value-based care in healthcare. "We are excited to continue supporting VentureMed in expanding access to this vital therapy," he stated, reaffirming the importance of this funding round.

VentureMed Group is committing to innovative endovascular solutions for arteriovenous (AV) access and peripheral artery disease (PAD) interventions, assisting healthcare providers in delivering advanced treatment options. For further details about their projects and products, visit VentureMed Group.